Debating the Science and Ethics of Synthetic Biology
News Nov 06, 2012
The panel, which includes Dr Helena Paul, Co-director of Econexus, Professor Robert Edwards, Chief Scientist of the Food and Environment Research Agency, Daisy Ginsberg, synthetic biology writer and commentator and Lionel Clarke, Chairman of the UK Synthetic Biology Roadmap Coordination Group, will take questions from the audience in Bristol and will respond to followers' questions on Twitter. The whole event will be webcast live and available to watch online.
For better or worse, synthetic biology is featuring more and more often in the media as scientists make new advances that attract headlines. News stories highlight some of the many ways in which synthetic biology could improve people's lives – from bio-energy and chemicals all the way through to drug delivery and regenerative medicine. But increased media attention also raises important issues around ethics, regulation and public acceptance.
The event – a collaboration between the Royal Society of Chemistry, the Biochemical Society, BioCentre and the University of Bristol – aims to stimulate discussion and inspire clear thinking about synthetic biology by bringing bring together senior members of the scientific community from industry and academia, along with policy makers to explore some of the questions and perceptions surrounding the subject.
Previous work by the International Multiple Sclerosis Genetics Consortium (IMSGC) has identified 233 genetic risk variants. However, these only account for about 20% of overall disease risk, with the remaining genetic culprits proving elusive. A new study has tracked down four of these hard-to-find genes.READ MORE
Scientists at McGill have found the answer to a question that perplexed Charles Darwin; if natural selection works at the level of the individual, fighting for survival and reproduction, how can a single colony produce worker ants that are so dramatically different in size – from “minor” workers to large-headed soldiers with huge mandibles – especially if they are sterile?
Scientists have developed a successful method to make truly personalized predictions of future disease outcomes for patients with certain types of chronic blood cancers. The study combined extensive genetic and clinical information to predict the prognosis for patients with myeloproliferative neoplasms.
2nd International Conference on Computational Biology and Bioinformatics
May 17 - May 18, 2019